IntegraGen Acquires Exclusive License to Metastatic Colon Cancer Biomarker | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it has acquired the exclusive rights to use a specific microRNA as a biomarker for predicting patient outcomes in metastatic colorectal cancer.

The license was obtained from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique — Hopitaux de Paris. Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.